Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer

(MedPage Today) -- A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news